Chemotherapy for Non-Small Cell Lung Cancer
Author Information
Author(s): C.J. Williams
Primary Institution: CRC Medical Oncology Unit, Southampton General Hospital
Hypothesis
Is chemotherapy a useful treatment for non-small cell lung cancer?
Conclusion
Chemotherapy should not be used as a routine therapy for non-small cell lung cancer until there is clear evidence of overall benefit.
Supporting Evidence
- Randomized trials have shown no survival benefit for adjuvant chemotherapy in 3,700 patients.
- Chemotherapy improved median disease-free survival by 7 months in one study.
- Combined modality therapy showed a 57% response rate compared to 40% for radiotherapy alone.
Takeaway
Chemotherapy for lung cancer might help some people live a little longer, but it can also make them feel very sick, so doctors are careful about when to use it.
Methodology
The paper reviews randomized trials examining the role of chemotherapy in non-small cell lung cancer.
Potential Biases
The studies discussed are highly selected and may not represent the general population.
Limitations
Many trials did not use a no-treatment control group, and the benefits of chemotherapy remain modest.
Participant Demographics
Patients with non-small cell lung cancer, including those with stages II and III disease.
Statistical Information
P-Value
P=0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website